Minerva Neurosciences (NASDAQ:NERV) hosted a virtual key opinion leader (KOL) event focused on its development candidate roluperidone for negative symptoms in schizophrenia, outlining the clinical ...
Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia February 3, 2026 10:30 ...
Schizophrenia, which is characterized by positive symptoms (e.g., hallucinations and delusions), negative symptoms (diminished emotional expressions or avolition), and cognitive impairments (attention ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results